Negar N Alami
Overview
Explore the profile of Negar N Alami including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
422
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kalluri H, Oberoi R, Chen Q, Jiang Q, Asatryan A, Alami N, et al.
Clin Pharmacol Drug Dev
. 2023 Sep;
12(10):945-955.
PMID: 37661787
Glecaprevir (GLE)/pibrentasvir (PIB) is an all-oral, interferon- and ribavirin-free, pan-genotypic fixed-dose combination regimen approved for the treatment of all major genotypes of hepatitis C virus (HCV) infection in many countries...
2.
Shebley M, Wang S, Ali I, Krishnan P, Tripathi R, Reardon J, et al.
Pharmacol Res Perspect
. 2022 Dec;
11(1):e01036.
PMID: 36537346
ABBV-47D11 is a neutralizing monoclonal antibody that targets a mutationally conserved hydrophobic pocket distal to the ACE2 binding site of SARS-CoV-2. This first-in-human safety, pharmacokinetics, and antiviral pharmacodynamic assessment in...
3.
Coutre S, Barnett C, Osiyemi O, Hoda D, Ramgopal M, Fort A, et al.
Open Forum Infect Dis
. 2022 May;
9(5):ofac104.
PMID: 35493119
Background: Few therapies are approved for hospitalized patients with severe coronavirus disease 2019 (COVID-19). Ibrutinib, a once-daily Bruton tyrosine kinase inhibitor, may mitigate COVID-19-induced lung damage by reducing inflammatory cytokines....
4.
Wei L, Wang G, Alami N, Xie W, Heo J, Xie Q, et al.
Lancet Gastroenterol Hepatol
. 2020 Jul;
5(9):839-849.
PMID: 32682494
Background: Glecaprevir-pibrentasvir results in high rates of sustained virological response in patients with chronic hepatitis C virus (HCV) genotype 1-6 infection. Data for glecaprevir-pibrentasvir in non-Japanese Asian patients have been...
5.
Grebely J, Dore G, Alami N, Conway B, Dillon J, Gschwantler M, et al.
Int J Drug Policy
. 2019 Feb;
66:73-79.
PMID: 30735896
Background: International guidelines recommend treatment of hepatitis C virus (HCV) infection in people who inject drugs (PWID), including those on opioid substitution therapy (OST). The pangenotypic combination of glecaprevir and...
6.
Grebely J, Puoti M, Wedemeyer H, Cooper C, Sulkowski M, Foster G, et al.
Open Forum Infect Dis
. 2018 Nov;
5(11):ofy248.
PMID: 30430131
Background: We evaluated the impact of opioid substitution therapy (OST) on the completion, adherence, efficacy, and safety of the 3-direct-acting antiviral regimen of ombitasvir, paritaprevir (identified by AbbVie and Enanta)...
7.
Al Hosani F, Kim L, Khudhair A, Pham H, Al Mulla M, Al Bandar Z, et al.
Clin Infect Dis
. 2018 Jun;
68(3):409-418.
PMID: 29905769
Background: Although there is evidence of person-to-person transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) in household and healthcare settings, more data are needed to describe and better understand the...
8.
Waked I, Esmat G, Fouad R, Allam N, Hassany M, Mohey M, et al.
J Med Virol
. 2018 Jun;
90(11):1739-1744.
PMID: 29900553
In AGATE-II, treatment with ombitasvir coformulated with paritaprevir/ritonavir plus ribavirin (RBV) in Egyptians infected with hepatitis C virus genotype 4 resulted in high rates of sustained virologic response at post-treatment...
9.
Al Hosani F, Pringle K, Al Mulla M, Kim L, Pham H, Alami N, et al.
Emerg Infect Dis
. 2016 Jun;
22(7):1162-8.
PMID: 27314227
In January 2013, several months after Middle East respiratory syndrome coronavirus (MERS-CoV) was first identified in Saudi Arabia, Abu Dhabi, United Arab Emirates, began surveillance for MERS-CoV. We analyzed medical...
10.
Hunter J, Nguyen D, Aden B, Al Bandar Z, Al Dhaheri W, Abu Elkheir K, et al.
Emerg Infect Dis
. 2016 Mar;
22(4):647-56.
PMID: 26981708
Middle East respiratory syndrome coronavirus (MERS-CoV) infections sharply increased in the Arabian Peninsula during spring 2014. In Abu Dhabi, United Arab Emirates, these infections occurred primarily among healthcare workers and...